​Phase III Study of Olaparib Plus Abiraterone Relative to Placebo plus Abiraterone as First Line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

​The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

Principal Investigator: Dr. Eric Knoche
Study Coordinator: Kelley Chadwick-Mansker

This study is currently enrolling. To learn more about PROpel and how you can join contact our research office at (314) 289-7690.

This study is funded by the Foundation through AstraZeneca